GlassScriptPhysician profile
Bradley Dean Chrisjohn
NPI 1013963727
$9,232.50
in general payments reported to CMS, 2019-2025
53 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $387 · 2021: $1,281 · 2022: $1,226 · 2023: $1,813 · 2024: $1,902 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,387.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,729.02 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,316.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $950.90 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $759.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $746.83 | 2019-2025 | |
| Abbott Laboratories | $695.44 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.48 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $262.55 | 2019-2023 | Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $200.76 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $198.34 | 2019-2023 | Xarelto, Spravato |
| Amarin Pharma, INC. | $182.45 | 2019-2022 | |
| Amgen INC. | $139.50 | 2019-2023 | Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $118.60 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Astellas Pharma US INC | $118.09 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $95.33 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Chrisjohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.